Table 3.

Adjuvant chemotherapy in gastric carcinoma: Randomized trials/meta-analysis

Studies	Country	Years	Randomization arms	Surgery	Protocol	Patients (n)	Overall survival	P value	Disease free survival	P value
ACTS-GC trial[25,26]	Japan	2007	Chemotherapy and surgery	D2 surgery	Oral S1 chemotherapy	529	71.7% at 5 yr1	-	65.4% at 5 yr1	-
			Surgery alone			530	61.1% at 5 yr		53.1% at 5 yr
GASTRIC metaanalysis[24]	-	2010	Chemotherapy	-	-	1924	55.3% at 5 yr1	< 0.001	54% at 5 yr1	< 0.001
			Surgery alone		-	1857	49.6% at 5 yr		48.7% at 5 yr
CLASSIC trial[27]	South Korea	2012	Chemotherapy and surgery	D2 surgery	XELOX chemotherapy	520	83% at 3 yr1	0.049	74% at 3 yr1	< 0.0001
			Surgery alone			515	78% at 3 yr		59% at 3 yr

¹Statistically significant result. XELOX: Xeloda and oxaliplatin.